Healthcare provider profile · identity verified

Wendy B Moose, NP

Nurse Practitioner · ASHEVILLE, NC · NPI 1386044501

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	239	39
Eliquis	Apixaban	208	17
Atorvastatin Calcium	Atorvastatin Calcium	205	30
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	186	11
Gabapentin	Gabapentin	181	22
Furosemide	Furosemide	173	26
Tramadol Hcl	Tramadol Hcl	172	46
Potassium Chloride	Potassium Chloride	161	31
Pantoprazole Sodium	Pantoprazole Sodium	158	40
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	150	30
Metoprolol Tartrate	Metoprolol Tartrate	134	17
Sertraline Hcl	Sertraline Hcl	125	22
Duloxetine Hcl	Duloxetine Hcl	123	16
Trazodone Hcl	Trazodone Hcl	122	19
Lisinopril	Lisinopril	116	22
Diclofenac Sodium	Diclofenac Sodium	107	23
Xarelto	Rivaroxaban	101	suppressed
Carvedilol	Carvedilol	95	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	95	15
Amlodipine Besylate	Amlodipine Besylate	94	21
Pregabalin	Pregabalin	89	19
Insulin Lispro Kwikpen U-100	Insulin Lispro	81	12
Olanzapine	Olanzapine	81	suppressed
Memantine Hcl	Memantine Hcl	75	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	74	15
Donepezil Hcl	Donepezil Hcl	71	12
Clonazepam	Clonazepam	67	16
Jardiance	Empagliflozin	67	suppressed
Lorazepam	Lorazepam	66	19
Buspirone Hcl	Buspirone Hcl	62	16
Divalproex Sodium	Divalproex Sodium	57	12
Omeprazole	Omeprazole	57	17
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	56	19
Tamsulosin Hcl	Tamsulosin Hcl	56	14
Levemir Flexpen	Insulin Detemir	55	suppressed
Oxycodone Hcl	Oxycodone Hcl	52	14
Promethazine Hcl	Promethazine Hcl	52	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	51	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	50	suppressed
Metoprolol Succinate	Metoprolol Succinate	49	suppressed
Prednisone	Prednisone	48	17
Allopurinol	Allopurinol	47	suppressed
Losartan Potassium	Losartan Potassium	47	11
Metformin Hcl	Metformin Hcl	47	suppressed
Risperidone	Risperidone	44	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	41	18
Aripiprazole	Aripiprazole	40	suppressed
Famotidine	Famotidine	40	suppressed
Fentanyl	Fentanyl	39	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	17
Nystatin	Nystatin	36	17
Ondansetron Hcl	Ondansetron Hcl	36	21
Divalproex Sodium Er	Divalproex Sodium	35	suppressed
Sucralfate	Sucralfate	35	suppressed
Insulin Aspart Flexpen	Insulin Aspart	33	suppressed
Latanoprost	Latanoprost	33	suppressed
Metformin Hcl Er	Metformin Hcl	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	suppressed
Levetiracetam	Levetiracetam	32	suppressed
Trulicity	Dulaglutide	32	suppressed
Benztropine Mesylate	Benztropine Mesylate	31	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	20
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	31	21
Finasteride	Finasteride	30	suppressed
Linzess	Linaclotide	29	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	suppressed
Memantine Hcl Er	Memantine Hcl	27	suppressed
Ozempic	Semaglutide	27	suppressed
Entresto	Sacubitril/Valsartan	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	23	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Alprazolam	Alprazolam	21	suppressed
Lacosamide	Lacosamide	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Novolog Flexpen	Insulin Aspart	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Lagevrio (Eua)	Molnupiravir	19	19
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Anastrozole	Anastrozole	18	suppressed
Lurasidone Hcl	Lurasidone Hcl	18	suppressed
Movantik	Naloxegol Oxalate	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Budesonide	Budesonide	17	suppressed
Ceftriaxone	Ceftriaxone Sodium	17	12
Cephalexin	Cephalexin	17	12
Baclofen	Baclofen	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Amantadine	Amantadine Hcl	15	suppressed
Bumetanide	Bumetanide	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Rexulti	Brexpiprazole	15	suppressed
Carbamazepine	Carbamazepine	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Lubiprostone	Lubiprostone	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Torsemide	Torsemide	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Isradipine	Isradipine	12	suppressed
Matzim La	Diltiazem Hcl	12	suppressed
Ertapenem	Ertapenem Sodium	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error